A study revealed in JAMA Network Open emphasizes the discrepancy in between what it prices to create copyright and the retail rates sufferers face. Despite the small generation costs, Novo Nordisk has not publicly disclosed certain figures for copyright or its other product or service, Wegovy.Novo Nordisk A/S is a Danish multinational pharmaceutica